Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Study reveals curcumin’s antidepressant effects in obese type 2 diabetes patients

A randomized clinical trial (RCT) to investigate the effectiveness of curcumin in lowering depression among obese individuals with diabetes mellitus type 2 (T2DM).

30 Jul 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

Weill Cornell researchers define three Parkinson's subtypes with machine learning

Researchers at Weill Cornell Medicine have used machine learning to define three subtypes of Parkinson's disease based on the pace at which the disease progresses.

16 Jul 2024

Study reveals potential cognitive benefits of antidiabetic drugs

Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.

12 Jul 2024

Four years non-diabetic status after impaired glucose tolerance diagnosis cuts cardiovascular risks

Maintaining non-diabetic status for at least four years after impaired glucose tolerance diagnosis significantly lowers the risk of cardiovascular complications and mortality.

10 Jul 2024

Semaglutide linked to increased risk of severe eye condition NAION in new study

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

8 Jul 2024

GLP-1 drugs found to lower cancer risk in diabetes patients

Research finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.

8 Jul 2024

PCOS linked to higher risk of adverse birth outcomes

The association between polycystic ovary syndrome (PCOS) and birth outcomes in women.

5 Jul 2024

Researchers identify key osteoporosis-related gene and develop new mouse model of the disease

Osteoporosis - weakening of the bones with age - affects millions worldwide, and this figure is increasing annually as the global population ages.

1 Jul 2024

Natural compound found in olives can lower blood sugar levels and promote weight loss

Findings from a new mouse study suggest that elenolic acid, a natural compound found in olives, can lower blood sugar levels and promote weight loss.

29 Jun 2024

Diabetes decoded: How your gut microbiome influences disease risk

How microbial features and functions specific to subspecies and strains contribute to the pathological mechanisms of type 2 diabetes.

27 Jun 2024

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

Researchers compare the effectiveness of anti-diabetes medications in reducing the risk of dementia in older diabetics.

26 Jun 2024

Mouse models inform potential treatments for Fragile X, Phelan-McDermid syndromes

Studies of mouse models of Fragile X syndrome and Phelan-McDermid syndrome show that treatment with cannabidiol (CBD) and the diabetes drug metformin can alleviate behavioral difficulties, according to research presented today (Wednesday) at the Federation of European Neuroscience Societies (FENS) Forum 2024.

26 Jun 2024

Semaglutide reduces heart risks in overweight and obese individuals without diabetes

The SELECT trial found that semaglutide significantly reduces cardiovascular events in individuals with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or changes in HbA1c levels.

26 Jun 2024

Semaglutide proves a game-changer for kidney and heart health in diabetes patients

The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.

25 Jun 2024

Targeting the gut microbiome: A new approach to treating diabetes

Researchers review the role of gut microbiota in the pathogenesis and management of diabetes mellitus.

24 Jun 2024

Intermittent fasting outperforms traditional drugs in managing early type 2 diabetes

Study shows that a 5:2 intermittent fasting meal replacement diet effectively controls blood glucose levels and reduces body weight in Chinese adults with early type 2 diabetes. This dietary intervention outperforms metformin and empagliflozin in managing diabetes and obesity.

24 Jun 2024

Metformin News and Research

Further Reading

Study reveals curcumin’s antidepressant effects in obese type 2 diabetes patients

Semaglutide may reduce smoking risks for diabetes patients

Weill Cornell researchers define three Parkinson's subtypes with machine learning

Study reveals potential cognitive benefits of antidiabetic drugs

Four years non-diabetic status after impaired glucose tolerance diagnosis cuts cardiovascular risks

Semaglutide linked to increased risk of severe eye condition NAION in new study

GLP-1 drugs found to lower cancer risk in diabetes patients

PCOS linked to higher risk of adverse birth outcomes

Researchers identify key osteoporosis-related gene and develop new mouse model of the disease

Natural compound found in olives can lower blood sugar levels and promote weight loss

Diabetes decoded: How your gut microbiome influences disease risk

Differences in effectiveness among antihyperglycemic drugs on dementia risk identified in recent study

Mouse models inform potential treatments for Fragile X, Phelan-McDermid syndromes

Semaglutide reduces heart risks in overweight and obese individuals without diabetes

Semaglutide proves a game-changer for kidney and heart health in diabetes patients

Targeting the gut microbiome: A new approach to treating diabetes

Intermittent fasting outperforms traditional drugs in managing early type 2 diabetes

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Integration of genomics, epigenomics, and transcriptomics in understanding Alzheimer's pathogenesis

Innovative therapeutic strategies for combating type 2 diabetes

Industry Focus eBook - Life Science Microscopy (3rd Edition) eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News